Sector
Healthcare
Industry
Biotechnology
Employees
108
First IPO Date
February 13, 2014
| Name | Title | Pay | Year Born |
| Laurent Levy | Co-Founder, President of the Executive Board & Chief Executive Officer | 844,959 | 1973 |
| Anne-Juliette Hermant | Chief People Officer & Member of Executive Board | 414,440 | 1974 |
| Bart Van Rhijn | Chief Financial & Business Officer and Member of Executive Board | 600,232 | 1974 |
| Louis Kayitalire | Chief Medical Officer & Member of Executive Board | 603,196 | 1959 |
| Anne-Sophie Lariviere | Chief Product Innovation & Delivery Officer | 0 | N/A |
| Brandon Owens | Vice President of Strategic Marketing & Corporate Communication | 0 | N/A |
| Earl J. Bergey | Co-Founder | 0 | 1955 |
| Margaret Galluzzi | Vice President & Global Head of Clinical Operations | 0 | N/A |
| Leonard A. Farber | Chief Clinical and Medical Affairs Officer & Chairman of the Scientific Advisory Board | 0 | N/A |
Nanobiotix S.A. is a clinical-stage biopharmaceutical company focused on advancing innovative therapeutic candidates for oncology. Its flagship investigational product, NBTXR3, is a sterile aqueous suspension composed of crystalline hafnium oxide nanoparticles. This unique nanotechnology-based agent is being evaluated for efficacy across a spectrum of malignant conditions, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. To broaden its global market reach, Nanobiotix has forged a strategic alliance with LianBio for the development and commercialization of NBTXR3 in key Asian territories such as Greater China, South Korea, Singapore, and Thailand. Established in 2003, the company maintains its corporate headquarters in Paris, France.